Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

13 Jul 2023

Abstract excerpt

Since the emergence of SARS-CoV-2, vaccines targeting COVID-19 have been developed with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the COVID-19 virus and the mRNA26 based Pfizer/BNT162b2 vaccines are widely distributed. Beyond the ability of vaccines to induce production of neutralizing antibodies, they might lead to the generation of antibodies attenuating the disease by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37443074
DOI: 10.1038/s41467-023-39189-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccinationPMID 37443074Read ↗

Waning and boosting of functional humoral immunity to SARS-CoV-2Semantic proximity Read ↗

mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concernSemantic proximity Read ↗

Resilient Fc-Effector Functions Across SARS-CoV-2 Variants of Concern Following mRNA-1273 VaccinationSemantic proximity Read ↗

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesSemantic proximity Read ↗

Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platformSemantic proximity Read ↗

BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with ageSemantic proximity Read ↗

Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation patternSemantic proximity Read ↗

Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccinesSemantic proximity Read ↗

Class switch toward IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccineesSemantic proximity Read ↗

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functionsSemantic proximity Read ↗

SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populationsSemantic proximity Read ↗

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.